This protocol is an extension of protocol 0002, Proof of Concept and Dose Ranging Study of
carbidopa-levodopa in Neovascular AMD. that is a 3 month study of escalating doses of
carbidopa-levodopa in neovascular AMD. This trial is a 9 month extension for patients who
successfully complete protocol 0002 and wish to continue carbidopa-levodopa therapy. It will
use the two higher dose regimens of protocol 0002. these will be assigned according to how
well the higher dose was tolerated in protocol 0002.
Phase:
Phase 2
Details
Lead Sponsor:
Snyder, Robert W., M.D., Ph.D., P.C.
Collaborator:
Snyder Biomedical Corporation
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa